PURPOSE: The purpose of this study is to describe initial experience with a new continuous flow, ventricular assist system in the pediatric population. DESCRIPTION: Seven children (aged 6 to 16 years) received implantation of a novel third-generation, continuous flow, ventricular assist device (HeartWare, HeartWare Inc, Miami Lakes, FL) as a bridge to cardiac transplantation. EVALUATION: All children were in terminal heart failure despite inotropic support, and signs of renal or hepatic impairment developed. Six children had dilatative cardiomyopathy and 1 had congenital heart disease (hypoplastic left heart, total cavopulmonary connections with extracardiac conduit). Six patients have been successfully bridged to transplantation. Median support time was 75 days (range, 1 to 136 days). One child is still under continuous mechanical support. None of the patients suffered a thromboembolic event or an infection. CONCLUSIONS: The HeartWare assist system can be successfully used as a bridge to transplantation in children and adolescents with end-stage heart failure.
PURPOSE: The purpose of this study is to describe initial experience with a new continuous flow, ventricular assist system in the pediatric population. DESCRIPTION: Seven children (aged 6 to 16 years) received implantation of a novel third-generation, continuous flow, ventricular assist device (HeartWare, HeartWare Inc, Miami Lakes, FL) as a bridge to cardiac transplantation. EVALUATION: All children were in terminal heart failure despite inotropic support, and signs of renal or hepatic impairment developed. Six children had dilatative cardiomyopathy and 1 had congenital heart disease (hypoplastic left heart, total cavopulmonary connections with extracardiac conduit). Six patients have been successfully bridged to transplantation. Median support time was 75 days (range, 1 to 136 days). One child is still under continuous mechanical support. None of the patients suffered a thromboembolic event or an infection. CONCLUSIONS: The HeartWare assist system can be successfully used as a bridge to transplantation in children and adolescents with end-stage heart failure.
Authors: David N Rosenthal; Christopher S Almond; Robert D Jaquiss; Christine E Peyton; Scott R Auerbach; David R Morales; Deirdre J Epstein; Ryan S Cantor; Robert L Kormos; David C Naftel; Ryan J Butts; Nancy S Ghanayem; James K Kirklin; Elizabeth D Blume Journal: J Heart Lung Transplant Date: 2016-03-17 Impact factor: 10.247
Authors: Carlo R Bartoli; Steven C Koenig; Constantine Ionan; Kevin J Gillars; Mike E Mitchell; Erle H Austin; Laman A Gray; George M Pantalos Journal: Pediatr Crit Care Med Date: 2013-11 Impact factor: 3.624
Authors: Veli K Topkara; James K O'Neill; Adam Carlisle; Eric Novak; Scott C Silvestry; Gregory A Ewald Journal: Ann Thorac Surg Date: 2013-10-17 Impact factor: 4.330